Trump officials seek price details as they assess most favored nation plan
Officials in President Donald Trump's administration have spent the month since his “most favored nation” drug price announcement trying to learn more about how pharma companies price their products...
View ArticleRFK Jr. names eight new ACIP members
Two days after firing all 17 members of the CDC’s vaccine advisory committee, HHS Secretary Robert F. Kennedy Jr. announced a new panel roughly half the size. Some of the new eight ...
View Article#EHA25: Schrödinger reports early Phase 1 data for MALT1 inhibitor
Schrödinger said its experimental MALT1 inhibitor showed early signs of safety and efficacy in an ongoing Phase 1 trial. The company also said the data support its broader computational discovery...
View ArticleBioNTech to acquire CureVac in all-stock deal valued at $1.25B
BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday. The acquisition gives an implied equity value of...
View ArticleCommons Clinic raises $26M Series B to offer preventive testing
Commons Clinic, a Los Angeles-based clinic chain focused on musculoskeletal care, has raised $26 million to test for and treat more conditions, Endpoints News learned exclusively. The startup is using...
View ArticleCapricor gets Form 483 from FDA; WuXi Biologics' new China factory
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Capricor Therapeutics has received a Form 483 from the FDA after an...
View ArticleADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for...
Plus, news about Blue Water, Enterome and BeOne Medicines: ADC Therapeutics launches $100M PIPE, discontinues some cancer work: The money is expected to help the company focus on its preclinical PSMA ...
View Article#EHA25: Kura, Kyowa say Phase 1 update supports menin inhibitor combos
As Kura Oncology and Kyowa Kirin await an FDA decision for their oral menin inhibitor in acute myeloid leukemia, the partners are highlighting another early cut of data for a combo with the drug in ...
View ArticleInsmed aims to raise $750M in one of the largest stock offerings this year
Insmed announced Thursday morning that it expects to raise $750 million in a stock sale, marking one of the largest public offerings by a biopharma company this year. The public offering ...
View ArticleTwo new ACIP picks were paid experts against Merck in court
Two of HHS Secretary Robert F. Kennedy Jr.’s new appointees to the CDC’s vaccine advisory board have previously served as paid expert witnesses for plaintiffs suing Merck over its HPV and MMR shots....
View ArticleFDA approves UroGen's bladder cancer hydrogel after negative adcomm vote
The FDA on Thursday approved UroGen’s application for its bladder cancer drug, despite a negative vote from an advisory committee last month. The drug, which UroGen will brand as Zusduri, is ...
View ArticleAnother care navigation deal
Capital Rx’s acquisition of Amino Health is the latest in a wave of consolidation in the care navigation space among companies that work with employers to connect their health plan ...
View ArticleCureVac CEO on the $1.25B BioNTech deal
After 25 years of trying to lead biopharma's mRNA revolution across infectious diseases and cancer, German biotech CureVac made the surprise announcement Thursday morning that it would exit to its...
View ArticleKennedy's doubts over vaccine placebos don't align with science, experts say
Much of HHS Secretary Robert F. Kennedy Jr.'s recent stated skepticism about vaccines is based on claims that many of the shots have never been tested against “inert” placebos. But experts interviewed...
View ArticleNovo Nordisk plans Phase 3 trials of oral, injectable amycretin
Novo Nordisk plans to go straight to Phase 3 with its experimental weight loss drug amycretin in the first quarter of 2026, the Danish drug giant said Thursday. The rush to late-stage testing signals...
View ArticleAppeals court upholds halt on Minnesota generic drug pricing law
A Minnesota drug pricing law violates the Constitution by allowing the state to essentially control prices outside of its borders, an appeals court ruled on Thursday. The US Court of Appeals for the...
View ArticleModerna wins FDA approval for expanded use of RSV shot in more adults
A little more than a week after Moderna’s new Covid-19 vaccine was approved, the FDA has expanded who can receive the company’s RSV shot. The agency approved mRESVIA on Thursday for at-risk adults 18...
View ArticleAstraZeneca, CSPC ink AI drug development deal for $110M upfront
AstraZeneca is further tightening its relationship with China, announcing a new research partnership with CSPC Pharmaceuticals on Friday. CSPC will receive $110 million upfront for the partners to...
View ArticleBristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs...
Just a few months ago, Chris Shibutani was asking Bristol Myers Squibb executives about their strategy during the drugmaker's quarterly earnings calls. As of Monday, the recently departed Goldman Sachs...
View ArticleRein Therapeutics study on clinical hold; Beam updates sickle cell therapy data
Plus, news about Enliven Therapeutics, Merck's Keytruda and Celldex: FDA places hold on Rein study: The agency has “non-clinical requests” for Rein Therapeutics’ Phase 2 trial in idiopathic pulmonary...
View Article